NAFDAC Alerts Nigerians To Suspected Fake Drug In Circulation
The National Agency for Food and Drug Administration and Control (NAFDAC) has warned the general public about a suspected fake Augmentin 625mg tablets in circulation within Nigeria.
NAFDAC said the particular Augmentin drug in circulation has no inscription written on the label.
The agency said it notified all its formations in the 36 states in the country to carry out surveillance and take the fake drug out of Nigeria.
“The product failed short of the labeling requirements. No inscription “manufactured by” is written on the label -only the address,” NAFDAC said in a statement.
“Manufacturing and expiry dates do not meet the acceptable format. No MAS scratch number for verification. The logo “gsk” is not properly positioned as on the original. The listed information indicates the product is falsified and counterfeited.”
NAFDAC draws the attention of the public to the detection of suspected falsified Augmentin 625mg Tablets in circulation within the country with the following details and labelling lapses;
The agency noted that the genuine Augmentin 625mg has legible product labeling information which includes expiry and manufacturing dates, batch number, and a NAFDAC registration number.
NAFDAC implores all healthcare providers to ensure vigilance to prevent the administration of falsified products to unsuspecting patients.
The agency also urged all wholesalers, distributors, and pharmacies to be vigilant and avoid infiltration of the falsified product, adding that medicines should be obtained from authorized and licensed suppliers.
“The products’ authenticity, physical condition, and labels should be carefully checked,” NAFDAC said
NAFDAC however urged the general public in possession of the suspected counterfeit product to discontinue sale or use and submit the stock to its nearest office.
“Healthcare providers and the public should notify the nearest NAFDAC office of any information concerning the distribution, sale, and use of the falsified version of the Augmentin product. Report any suspicion of adverse drug reaction and substandard and falsified medicines to NAFDAC.”
